AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05754671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perceptual assessment of the recorded voice sample
Description: perceptual assessment of the recorded voice samples
Study NCT05754671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: voice recording
Description: voice recording
Study NCT00939588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/ Valsartan
Study NCT00939588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/ Ramipril
Study NCT00770744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10-15mg/day; orally, encapsulated tablets, once daily
Study NCT02690116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong/Tai Chi Easy
Description: Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
Study NCT02690116 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Qigong
Description: Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
Study NCT02690116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Support
Description: Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
Study NCT01133080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
Study NCT01133080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.
Study NCT05840068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: MetFORMIN 500 Mg Oral Tablet
Study NCT05840068 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
Study NCT05840068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
Study NCT00171912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT01451502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood (UCB)
Description: Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
Study NCT04848818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial metaphyseal fracture fixation with percutaneous K-wires
Description: Pediatric distal metaphyseal fractures which are severly displaced will be operated with percutaneous K-wires..
Study NCT04848818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial and/or ulnar metaphyseal fracture fixation with bidegradable PLGA-based (Activa Im-Nail) implants
Description: Pediatric distal metaphyseal radial and /or ulnar fractures which are severly displaced will be operated with percutaneous bidegradable PLGA-based (Activa Im-Nail) implants.
Study NCT01016847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10 mg Q day
Study NCT01016847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill that looks like Montelukast that will be given Q day
Study NCT04351308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAPI chemotherapy
Description: AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)
Study NCT04351308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAPI chemotherapy
Description: AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)
Study NCT04351308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily
Study NCT04351308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: anti-PD-1 antibody 200mg ivgtt. Q2W
Study NCT02079025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound guided prostate biopsy
Description: Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system
Study NCT02079025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ultrasound guided prostate biopsy
Description: Ultrasound guided prostate biopsy using standard of care ultrasound system
Study NCT03566745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood for protein activity
Description: Blood for protein activity
Study NCT03265353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Moderate Potassium/Low Sodium Diet
Description: 7 days of the prescribed diet
Study NCT03265353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Moderate Potassium/High Sodium Diet
Description: 7 days of the prescribed diet
Study NCT03265353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Potassium/High Sodium Diet
Description: 7 days of the prescribed diet
Study NCT04196634 — intervention group
Intervention type: OTHER
Intervention: Risk assessment
Description: People on sick leave due to musculoskeletal conditions will be screened for potential risk factors for prolonged sickness absence. No intervention will be given.
Study NCT04276051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation of the Vagus Nerve
Description: The Visual ICE Cryoablation System is a mobile console system intended for cryoablative tissue destruction using a minimally invasive procedure. The Visual-ICE System uses high-pressure argon gas that circulates through closed-tip cryoablation needles to induce tissue freezing. Active tissue thawing is achieved by circulating helium gas through the needles or, alternatively, by the use of Galil Medical i-Thaw technology. The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40 degrees Celsius) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.
Study NCT04276051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.
Study NCT04276051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.
Study NCT05661318 — intervention group
Intervention type: OTHER
Intervention: Risk assessment
Description: Collect clinical, laboratoary and genetics data from the participants after informed consent
Study NCT03462862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
Study NCT03462862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bre-Flex
Description: In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality.
Study NCT00566891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirofiban
Description: tirofiban high dose bolus 25µ/Kg
Study NCT00566891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Study NCT04081064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-week exercise programme based on aerobic interval and resistance training
Description: The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
Study NCT03647761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetra-grip
Description: Tetra-grip is a tubular elastic bandage that provides both compression and support
Study NCT00763490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full intensity, double umbilical cord, stem cell transplant
Description: stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
Study NCT00763490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu/Bu4 conditioning regimen
Description: Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2
Study NCT00763490 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Description: one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
Study NCT00763490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graft versus Host Disease prevention (GVHD prophylaxis)
Description: Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
Study NCT00763490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) \< 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.~MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued.
Study NCT02924090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
Study NCT02924090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
Study NCT02924090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperventilation
Description: Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
Study NCT02924090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
Study NCT03072524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FAST PLUS test
Description: FAST PLUS test consists of two parts: the first one is the standard FAST test, which evaluates Speech (0-1), Facial palsy (0-1), Arm motor function (0-1), Time (0-1). The second part of the FAST PLUS test evaluates only the presence of severe arm or leg motor deficit (0-1), and unilateral occurrence of this motor function deficit (0-1).
Study NCT00604708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51
Description: IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
Study NCT00604708 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE-VAX
Description: JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
Study NCT03648359 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: multiparametric MRI Diagnostics
Description: Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found
Study NCT00267514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)
Description: sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks
Study NCT00267514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)
Description: sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
Study NCT03846440 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study NCT00499967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9191 ointment
Description: GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
Study NCT00499967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9191
Description: GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
Study NCT00499967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GS-9191 ointment
Study NCT03570723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A glove-loaded Foley's catheter tamponade
Description: A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
Study NCT03570723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stepwise uterine devascularization
Description: Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os.
Study NCT02984007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.~The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
Study NCT00833404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Description: 8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
Study NCT04325867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-medicine platform
Description: Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
Study NCT00784589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Corticotherapy
Description: for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
Study NCT00784589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
Study NCT05034380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute exercise
Description: All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.
Study NCT05034380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.
Study NCT01737879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: All participants will receive peginesatide for the first 24 weeks.
Study NCT01737879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: All participants converted to epoetin alfa at week 25 for a total of 32 weeks